Funding news
Anagram Therapeutics, Inc. logo

Anagram Therapeutics, Inc. Raises $250.

Recently funded · $250.0M UnknownHospitals and Health CareUSView source

Get the full Anagram Therapeutics, Inc. company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Anagram Therapeutics, Inc., a clinical stage company tackling complex gastrointestinal diseases, has raised $250.0M to advance its pipeline of enzyme-based therapies.

The company specializes in proprietary enzyme technologies aimed at solving malabsorption syndromes and nutrient metabolism disorders, which prevent the body from properly processing essential nutrients. Its lead product, ANG003, is a new class of broad-spectrum digestive enzyme replacement therapy intended for conditions like exocrine pancreatic insufficiency and malabsorption, offering a potential life-changing impact for patients with cystic fibrosis and other rare diseases.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#CompanyAmount
1
MN8 Energy logo

MN8 Energy

Spain

$87.5M
2
Every Financial Solution logo

Every Financial Solution

$23.5K
3
Buyerlink logo

Buyerlink

United States

$40.0M
4
Greenboard logo

Greenboard

United States

$20.0M
5
Odys Aviation logo

Odys Aviation

United States

$172.8K